Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2025-09-05 M&A Activity
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the acquisition of shares in another company (타법인 주식 및 출자증권 양수결정). This is a standard regulatory disclosure for material corporate events, specifically M&A-related activity involving the purchase of equity in another entity. Since it details the acquisition terms, valuation, and board approval, it falls under the category of M&A activity.
2025-09-05 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange, specifically detailing the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). This document outlines the terms of the financing, including interest rates, conversion prices, and the purpose of the funds (acquisition of shares in another company). In the context of financial filings, this falls under capital structure changes and financing activities, which is classified as 'Capital/Financing Update' (CAP).
2025-09-05 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea for reporting significant changes in share ownership (often referred to as the '5% rule' filing). The document explicitly details the reporting of shareholding changes, including the reason for the change (third-party allocation capital increase and off-market sale) and the updated shareholding percentages. This falls under the 'Major Shareholding Notification' category.
2025-09-02 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Directors and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a regulatory filing in South Korea (DART system) used to disclose insider transactions or changes in ownership by major shareholders. This falls under the 'Director's Dealing' category as it details the shareholding changes of a major shareholder (Song Kee Ryoung) in SCM Lifescience Co., Ltd.
2025-09-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details a change in share ownership (specifically a decrease due to off-market sales) by a major shareholder (Song Kee Ryoung) in SCM Lifescience Co., Ltd. This type of filing is used to notify the market of significant changes in shareholding thresholds, which falls under the 'Major Shareholding Notification' category.
2025-09-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details a change in share ownership by a major shareholder (Song Kee Ryoung) of SCM Lifescience Co., Ltd. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) in the provided schema, as it reports personal share transactions by a major shareholder/insider.
2025-09-01 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.